These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31309259)

  • 1. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate
    Maaland AF; Heyerdahl H; O'Shea A; Eiriksdottir B; Pascal V; Andersen JT; Kolstad A; Dahle J
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2311-2321. PubMed ID: 31309259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003.
    Maaland AF; Saidi A; Torgue J; Heyerdahl H; Stallons TAR; Kolstad A; Dahle J
    PLoS One; 2020; 15(3):e0230526. PubMed ID: 32187209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
    Dahle J; Repetto-Llamazares AH; Mollatt CS; Melhus KB; Bruland OS; Kolstad A; Larsen RH
    Anticancer Res; 2013 Jan; 33(1):85-95. PubMed ID: 23267131
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Giesen D; Hooge MNL; Nijland M; Heyerdahl H; Dahle J; de Vries EGE; Pool M
    Sci Rep; 2022 Apr; 12(1):6286. PubMed ID: 35428777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of
    Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
    Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
    Repetto-Llamazares AH; Larsen RH; Patzke S; Fleten KG; Didierlaurent D; Pichard A; Pouget JP; Dahle J
    PLoS One; 2015; 10(6):e0128816. PubMed ID: 26066655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
    Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of [
    Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro.
    Malenge MM; Maaland AF; Repetto-Llamazares A; Middleton B; Nijland M; Visser L; Patzke S; Heyerdahl H; Kolstad A; Stokke T; Ree AH; Dahle J
    PLoS One; 2022; 17(4):e0267543. PubMed ID: 35486574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
    Thakral P; Singla S; Yadav MP; Vasisht A; Sharma A; Gupta SK; Bal CS; ; Malhotra A
    Indian J Med Res; 2014 Apr; 139(4):544-54. PubMed ID: 24927340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
    Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
    Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
    Seidl C; Zöckler C; Beck R; Quintanilla-Martinez L; Bruchertseifer F; Senekowitsch-Schmidtke R
    Eur J Nucl Med Mol Imaging; 2011 Feb; 38(2):312-22. PubMed ID: 21072513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Malenge MM; Patzke S; Ree AH; Stokke T; Ceuppens P; Middleton B; Dahle J; Repetto-Llamazares AHV
    J Nucl Med; 2020 Oct; 61(10):1468-1475. PubMed ID: 32245896
    [